DocWire News Editors

DocwireNews

In a presentation about anaphylaxis titled &ldquo;Early Use of Epinephrine: What&rsquo;s the Evidence?&rdquo; speaker Jay A. Lieberman, MD, of the University of Tennessee Health Science Center and Le Bonheur Children&rsquo;s Hospital in Memphis, took a devil&rsquo;s advocate approach to the question.There is currently an absence of any placebo-controlled experimental trials in humans to show epinephrine&rsquo;s efficacy in anaphylaxis, he said. Therefore, clinicians must review and apply other applicable data, as well as consider the goals: to decrease costs, morbidity, and mortality.Animal studies have had &ldquo;fascinating results,&rdquo; he said. In a rabbit model, epinephrine resulted in an increased mean arterial pressure (MAP) compared with thyrotropin-releasing hormone (TRH) and normal saline one minute after treatment. However, TRH showed increased MAP over epinephrine at four minutes, and there were no differences in MAP among the three groups beyond four minutes. Furthermore, the study found no difference in survival between treated and control animals.In a canine study of anaphylactic shock, researchers compared three methods of epinephrine administration versus respective placebos given once hypotension started. The study found that earlier administration of intravenous epinephrine (before maximal hypotension) may produce a more beneficial effect. Another canine model study Lieberman reviewed found that bolus treatment of epinephrine by three methods, when administered at the initiation of allergen challenge, led to limited hemodynamic improvement.The closest in vivo study in humans, he said, found that standard therapy with epinephrine and fluids, did not immediately reverse the hemodynamic or respiratory abnormalities in the two subjects who had the most severe anaphylactic shock.&ldquo;So why do we continually recommend early epinephrine?&rdquo; Lieberman asked. He noted that case series of fatalities due to anaphylaxis suggest that fatal cases do not receive epinephrine or receive it late. Additionally, studies have shown that administration of epinephrine before arrival in the emergency department is independently associated with a decreased likelihood of requiring multiple doses of epinephrine, decreased hospitalization, and decreased admission to the intensive care unit.Regardless, the literature shows that some reactions will be fatal whether epinephrine is administered early or not. Lieberman stressed that although epinephrine may be crucial in managing reactions to stings, research has found that inhaled beta agonists may be more important in anaphylaxis cases that are due to food allergy.&ldquo;There&rsquo;s a lot of noise out there,&rdquo; he added, but conceded that the limited supportive data and the lack of a downside leads him to choose to administer it and to do so early.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Debating the Early Use of Epinephrine

ACAAI 2018

In a presentation about anaphylaxis titled “Early Use of Epinephrine: What’s the Evidence?” speaker Jay A. Lieberman, MD, of the University of Tennessee Health Science ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe